Evidence map›Paper›PMID 41232998›Full record

ReviewNeurologic clinics2026

Epilepsy and Placebo: A Literature Review.

David A Klodowski, Shira R Goldenholz, Daniel M Goldenholz

Abstract readReview
In one paragraph

Review in Neurologic clinics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David A KlodowskiDepartment of Neurology, Beth Israel Deaconess Medical Center, Baker 5. 330 Brookline Avenue, Boston, MA 02215, USA.
Shira R GoldenholzDepartment of Neurology, Beth Israel Deaconess Medical Center, Baker 5. 330 Brookline Avenue, Boston, MA 02215, USA.
Daniel M GoldenholzDepartment of Neurology, Beth Israel Deaconess Medical Center, Baker 5. 330 Brookline Avenue, Boston, MA 02215, USA. Electronic address: daniel.goldenholz@bidmc.harvard.edu.

Funding

Non-Invasive Seizure Forecasting System Using E-Diaries, Internal and External FactorsK23NS124656 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Daniel M Goldenholz · 2022 to 2026
$954k
NINDS NIH HHS K23 NS124656
6 · The paper itself

Abstract

Epilepsy is a widespread neurologic illness with high morbidity. Further treatments are needed to limit ongoing injury. To demonstrate effectiveness of new treatments, randomized controlled trials comparing adjuvant treatment to placebo are used. Larger placebo response limits trial sensitivity to an effective drug. Placebo also influences many other aspects of epilepsy, including intracranial electroencephalography, nocebo, device treatments, among others. Recent advances in modeling suggest that a true placebo effect in epilepsy treatment trials is possibly nil and that placebo response may be due to natural fluctuation alone, although further studies are necessary.

Indexed as

AnticonvulsantsEpilepsyPlacebo EffectHumansAnticonvulsantsClinical trialsEpilepsyNatural variabilityPlaceboSimulation

Identifiers

PMID41232998
PMCPMC12983173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.